Search results
Corbus Pharmaceuticals shares rally on raised price target, Outperform rating By Investing.com
Investing.com· 3 days agoOppenheimer has raised the price target on Corbus Pharmaceuticals (NASDAQ:CRBP) shares to $80 from...
Stars Who Have Taken a Break From Acting
SheKnows via Yahoo News· 19 hours agoRegardless of what job you do, all of us need a little break sometimes. And though we all idealize what being a famous actor would be like, many of our...
Cillian Murphy Irish Drama ‘Small Things Like These’ Lands at Lionsgate
The Hollywood Reporter· 18 hours agoCillian Murphy’s Oppenheimer follow-up, the Irish drama Small Things Like These, has landed at...
Cillian Murphy finally breaks his silence on his Peaky Blinders return – and the movie is officially...
Games Radar· 1 day agoCillian Murphy has finally broken his silence on the upcoming Peaky Blinders movie – and confirmed...
Q3 2024 Guidewire Software Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 20 hours agoLLC Dylan Becker; Analyst; William Blair Ken Wong Wong; Analyst; Oppenheimer & Co. Inc. Peter Heckmann Heckmann; Analyst; D.A. Davidson & Co. Rishi Jaluria Jaluria; Analyst ...
Immunovant Inc (IMVT) receives an Outperform rating from Oppenheimer – Knox Daily
Knox Daily· 11 hours agoAs a result of the transaction, Butchko Julia G. now holds 448,380 shares, worth roughly $11.31 million. Oppenheimer initiated its Immunovant Inc [IMVT] rating to an Outperform ...
A $400K San Francisco Bay Area property surfaces, but there’s a catch — it’s underwater
Sacramento Bee via AOL· 12 hours agoThe lot was originally part of the San Francisco Bay tideland and one of three parcels — 610, 650...
Lululemon Athletica Recovering From Merchandising Missteps, Says Analyst - Lululemon Athletica...
Benzinga· 2 days agoOppenheimer analyst Brian Nagel reiterated an Outperform rating on the shares of Lululemon Athletica...
Oppenheimer maintains 'Outperform' on CATX with $2 target By Investing.com
Investing.com· 7 days agoOn Thursday, Oppenheimer reiterated an Outperform rating on Perspective Therapeutics Inc (NYSE:CATX)...
Oppenheimer's Stoltzfus Says S&P Could Top 5,500 by Year-End
Bloomberg· 6 days agoOppenheimer's John Stoltzfus says the S&P 500 could top 5,500 by the end of the year. He says...